Novel VHL ligand-based PROTACs targeting JNK1: design, synthesis, and biological evaluation with potent anti-EMT activity
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Shuhua Ren und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, C…. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Drug Design, Von Hippel-Lindau Tumor Suppressor Protein, Mitogen-Activated Protein Kinase 8. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Epithelial-mesenchymal transition (EMT) is essential for embryogenesis and tissue regeneration, yet its aberrant activation is closely associated with organ fibrosis and tumor metastasis. c-Jun N-terminal kinase 1 (JNK1) has been identified as a key mediator of transforming growth factor-β (TGF-β)-driven EMT, making it a promising therapeutic target. Herein, we describe the design, synthesis, and biological evaluation of a series of JNK1-targeting PROTACs that recruit either CRBN or VHL E3 ligases. Systematic structure-activity relationship optimization led to the discovery of compound YC2, which incorporates a newly developed VHL ligand modified with a 2,4-dimethyloxazole moiety, as a potent and selective degrader. YC2 induced efficient, concentration- and time-dependent degradation of JNK1 (DC₅₀ of 4.90 nM) via VHL-mediated ubiquitin-proteasome pathway engagement, while displaying strong selectivity over related kinases including JNK2, p38α, and ERK. Moreover, YC2 markedly attenuated TGF-β1-induced EMT, as evidenced by reduced fibronectin levels and restoration of E-cadherin expression, with efficacy comparable to nintedanib. Collectively, YC2 featuring a novel VHL ligand demonstrates excellent degradation potency and selectivity for JNK1, highlighting its potential as a valuable chemical probe for EMT-associated pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
- School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Key Laboratory of Element Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chine…
- Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, TX 78229, USA.
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China. Electronic address: malei@ecust.edu.cn.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Ren, S., Zhang, Y., Hao, R., Yuan, J., Chi, M., Cai, W., Gu, W., Huang, Y., Yuan, Y., Chen, X., & Ma, L. (2026). Novel VHL ligand-based PROTACs targeting JNK1: design, synthesis, and biological evaluation with potent anti-EMT activity. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110388
Vancouver
Ren S, Zhang Y, Hao R, Yuan J, Chi M, Cai W, et al. Novel VHL ligand-based PROTACs targeting JNK1: design, synthesis, and biological evaluation with potent anti-EMT activity. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110388
BibTeX
@article{Ren2026,
author = {Ren, Shuhua and Zhang, Ye and Hao, Rui and Yuan, Jiale and Chi, Man and Cai, Weiqi and Gu, Wenjing and Huang, Yi and Yuan, Yaxia and Chen, Xiabin and Ma, Lei},
title = {Novel VHL ligand-based PROTACs targeting JNK1: design, synthesis, and biological evaluation with potent anti-EMT activity},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110388}
}
EUVIMED